Acticor Biotech Stock Quote ALACT - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

0.48

Bid

0.48

Ask

0.50

Volume

21,841

0.48 Day's Range 0.51

0.27 52 Week Range 6.00

Market Cap

7.563M

Previous Close

0.54

Open

0.51

Last Trade

250

0.48

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

76,550

Shares Outstanding

15,755,227

Dividend Yield

PE Ratio

-0.48

Earnings Per Share (EPS)

-1.01

Revenue

2.7M

Net Profit

-15.88M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.acticor-biotech.com

Headquarters

Paris, Paris, Fra

Founded

1970

Acticor Biotech is listed in the Pharmaceutical Preparations sector of the Euronext with ticker ALACT. The last closing price for Acticor Biotech was 0.54 €. Over the last year, Acticor Biotech shares have traded in a share price range of 0.27 € to 6.00 €.

Acticor Biotech currently has 15,755,227 shares outstanding. The market capitalization of Acticor Biotech is 8.51 € million. Acticor Biotech has a price to earnings ratio (PE ratio) of -0.48.

Acticor Biotech Announces the Conclusions of the Interim Futility Analysis in the GREEN Study

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies...

ACTICOR BIOTECH : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC LA SOCIÉTÉ DE BOURSE KEPLER CHEUVREUX

Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT), société biopharmaceutique au stade clinique qui développe le glenzocimab, un médicament innovant pour le traitement des urgences...

Acticor Biotech : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 30 juin 2024

Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT), société biopharmaceutique au stade clinique qui développe...

Acticor Biotech publishes its 2023 annual results

Annual General Meeting to be held on September 13, 2024, to approve the financial statements for the year ending December 31, 2023 Update on the glenzocimab clinical development plan published...

Acticor Biotech: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 mai 2024

Acticor Biotech fait le point sur le plan de développement clinique du glenzocimab dans le traitement des urgences cardio-vasculaires

Nouvelles analyses de l’étude de phase 2/3 ACTISAVE démontrant des tendances favorables pour le glenzocimab sur des sous-populations de patients Poursuite des études cliniques : GREEN de phase...

Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies

Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies New analyses of ACTISAVE phase 2/3 study show positive trends for...

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2024

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies...

The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack

University of Birmingham and Acticor Biotech News ReleaseLimited clinical access available The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first...

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke 438 patients with stroke have been randomized in ACTISAVE study evaluating glenzocimab, in...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.09	-15.7894736842	0.57	0.57	0.48	3581	0.54410792	DE
4	-0.23	-32.3943661972	0.71	0.71	0.421	12955	0.53844907	DE
12	0.091	23.3933161954	0.389	1.24	0.38	76550	0.86447541	DE
26	-3.92	-89.0909090909	4.4	5.3	0.27	71186	1.06682831	DE
52	-5.06	-91.3357400722	5.54	6	0.27	37947	1.28819274	DE
156	-6.62	-93.2394366197	7.1	11	0.27	15789	2.03663161	DE
260	0.307	177.456647399	0.173	11	0.11	65984	1.20486665	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WINTWindtree Therapeutics Inc	$ 8.24 (150.46%)	48.57M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NBSTWNewbury Street Acquisition Corporation	$ 0.1349 (92.71%)	122.1k
YIBOPlanet Image International Ltd	$ 2.915 (53.43%)	260.07k
CREVCarbon Revolution Public Ltd	$ 9.00 (45.87%)	8.06M
NMHINatures Miracle Holding Inc	$ 0.2035 (-48.06%)	7.69M
TANHTantech Holdings Ltd	$ 0.2585 (-47.23%)	6.75M
DXCMDexCom Inc	$ 64.00 (-40.66%)	53.92M
PSIGPS International Group Ltd	$ 1.42 (-31.40%)	716.26k
POAIPredictive Oncology Inc	$ 1.36 (-27.27%)	6.02M
SLNASelina Hospitality PLC	$ 0.0305 (-18.88%)	408.61M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NVDANVIDIA Corporation	$ 113.06 (0.69%)	293.33M
SQQQProShares UltraPro Short QQQ	$ 9.10 (-2.88%)	176.49M
SGMOSangamo Therapeutics Inc	$ 0.8612 (28.15%)	123.71M